QTRX News & Events

Quanterix is issuing its initial guidance for 2026. The Company expects revenues of $169 to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49% to 53%. Quanterix expects to achieve cash flow breakeven performance in the second half of 2026. The company expects to exit the year with approximately $100 million in cash and no debt.

Reports Q4 revenue $43.9M, consensus $38.0M. "I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth," said Everett Cunningham, President & CEO of Quanterix. "During the fourth quarter, we exceeded our revenue expectations, we continued to move the company closer to profitability, and we achieved key milestones in our Alzheimer's Diagnostics business. With most of the major integration milestones now behind us, our focus now turns to driving consistent profitable revenue growth and achieving cash flow breakeven performance in 2026. My immediate focus is on spending time with the Quanterix team, customers, shareholders, and partners as I evaluate the Company's strategy and future potential and ensure that we have the resources, support and capabilities to deliver on our operational priorities. I am extremely optimistic for what the future holds for Quanterix."

Quanterix announced it has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer's disease detection. The test, which previously received Breakthrough Device Designation, is intended to aid in identifying patients with cognitive symptoms likely to have amyloid brain plaques. Quanterix stated the test utilizes its Simoa technology to measure a panel of five key analytes.

Quanterix Corporation announced that its Board of Directors has appointed Everett Cunningham as the company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Cunningham assumes the role on January 19, 2026. Following Cunningham's start date, Toloue will remain available to the company in an advisory capacity to support continuity and help ensure a smooth leadership transition. Contemporaneous with Cunningham's appointment, Bill Donnelly, Executive Chair of the Board, will transition to his prior role as non-executive Chair of the Board. "We are excited to welcome Everett to Quanterix," said Bill Donnelly, Executive Chair of the Board. "Throughout his career, Everett has demonstrated his ability to accelerate growth at both research tools and diagnostics companies, build high-performing commercial organizations and lead transformational change at scale. His deep understanding of our customers and markets and his track record of operational execution makes him exceptionally well suited to lead Quanterix in its next phase of growth."